Elevated platelet-derived growth factor-BB concentrations in premature neonates who develop chronic lung disease

BMC Pediatrics

Table 1 Clinical Characteristics of Study Subjects

	Off Oxygen at 28 days (n = 16)	Oxygen at 28 days (n = 28)	Died (n = 6)	P value¹	P value²
Birth Weight	1112 ± 47	799 ± 35	751 ± 101	<0.001	0.002
Gestation	27.9 ± 0.4	26.1 ± 0.3	24.5 ± 0.6	0.001	<0.001
Surfactant	16 (100)	27 (96)	6 (100)	1.00	1.00
Prenatal Steroids	14 (88)	19 (68)	3 (50)	0.278	0.100
Uu isolated	4 (25)	14 (50)	2 (33)	0.105	1.000
PDA	7 (44)	14 (50)	3 (50)	0.835	1.000
Indomethacin³	13 (81)	28 (100)	6 (100)	0.042	0.532
Duration IMV (days)	8 ± 1	40 ± 6	15 ± 1	<0.001	0.013
Duration O₂ (days)	19 ± 3	79 ± 9	15 ± 1	<0.001	0.479
Postnatal Steroids	5 (31)	25 (89)	6 (100)	<0.001	0.012
Age Steroids Started	11.6 ± 2.8	11.5 ± 1.5	6.8 ± 3.0	0.973	0.129
PH	0(0)	7 (25)	3 (50)	0.037	0.013
IVH	2 (13)	12 (43)	3 (50)	0.039	0.100

Data are presented as Mean ± SEM or number with percentage in parenthesis ¹ O₂ at 28 days vs not on O₂ at 28 days ²deaths vs not on O₂ at 28 days ³Indomethacin was used prophylactically in most cases Uu Ureaplasma urealyticum PDA Patent ductus arteriosus PH Pulmonary hemorrhage IVH Intraventricular hemorrhage

ISSN: 1471-2431